Skip to main content
Julio Chavez, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

JulioCChavezMD

Oncology • Tampa, FL

Hematologic Oncology

Physician

Request Appointment

Overview of Dr. Chavez

Dr. Julio Chavez is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. He received his medical degree from Cayetano Heredia University and has been in practice 17 years. He is one of 172 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 52 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of South Florida Morsani
    University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2011 - 2013
  • University at Buffalo
    University at BuffaloResidency, Internal Medicine, 2008 - 2011
  • Cayetano Heredia University
    Cayetano Heredia UniversityClass of 2000

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2013 - 2026
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Axicabtagene Ciloleucel (KTE-C19), an Anti-CD19 CAR T Therapy for the Treatment of relapsed/refractory Aggressive B-cell Non-Hodgkin’s Lymphoma  
    Julio C Chavez, Vania H Phuoc, Therapeutics and Clinical Risk Management

Abstracts/Posters

  • A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...
    Julio C. Chavez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
    Julio C. Chavez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Retrospective Single-Institution Analysis
    Julio C. Chavez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell Lymphoma
    Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell LymphomaDecember 23rd, 2023
  • Long-Term Data for Kite’s Yescarta® CAR T-cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients with High-Risk Large B-cell Lymphoma
    Long-Term Data for Kite’s Yescarta® CAR T-cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients with High-Risk Large B-cell LymphomaDecember 13th, 2023

Hospital Affiliations

Dr. Julio Chavez, Dr. Julio Chavez, MD, Dr. J Chavez, Dr. Julio C Chavez